Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lozivate-3S
- Development stage
- Unknown
- Lead developer
- Canixa Life Sciences
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Lozivate-3S is a topical combination medication developed by Canixa Life Sciences, containing the potent corticosteroid clobetasol propionate (0.05%) and the keratolytic agent salicylic acid (3%). It is formulated as a lotion and an ointment for the treatment of inflammatory, hyperkeratotic, and scaly skin conditions such as plaque psoriasis, eczema, and chronic dermatitis. Clobetasol propionate acts as a glucocorticoid receptor agonist, reducing inflammation, redness, and itching by inhibiting the release of pro-inflammatory mediators. Salicylic acid acts as a keratolytic agent that softens and descales the outer layer of the skin, promoting the shedding of dead skin cells and enhancing the penetration of clobetasol propionate into the skin.
- Brand names
- Lozivate-3SLozivate3SLozivate 3SLozivate-3S LotionLozivate3S LotionLozivate 3S LotionLozivate-3S OintmentLozivate3S OintmentLozivate 3S Ointment
- Other names
- clobetasol propionate + salicylic acid
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on Lozivate-3S.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lozivate-3S.